Leucovorin calcium is indicated for patients who underwent high dose methotrexate treatment for osteosarcoma. Leucovorin calcium is also indicated to counteract the adverse events of folate antagonists and methotrexate elimination. Leucovorin calcium is also prescribed for the management of megaloblastic anemia due to folate deficiency in patients who are unresponsive to oral therapy.
In palliative care, Leucovorin calcium is indicated as a combined therapy with 5-FU to improve survival rate in advanced stage colorectal carcinoma patients.
No information available
No information available
No information available
Leucovorin Calcium can cause vomiting, leucopenia, infection, nausea, anorexia, dermatitis, alopecia, malaise or lethargy and drug toxicity.
Do not give Leucovorin Calcium intrathecally. It can cause fatal reactions.
No information available
Leucovorin Calcium may increase the toxicity of 5-FU.
No information available
Consider administration of Leucovorin Calcium at 200 mg/m2 as slow IV over three minutes followed by IV 5-FU at the rate of 370 mg/m2. Repeat the treatment for five days with an interval of 28 days.
No information available
USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are in gestation or planning to have a baby during Leucovorin calcium treatment.
It is not known whether Leucovorin calcium can pass through the breast milk or not. Nursing mothers should avoid breastfeeding while taking Leucovorin calcium.
Leucovorin Calcium should not be used in children unless prescribed by a pediatrician
No information available
No information available
No information available
No information available
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.